The growing field of liquid biopsy and its Snowball effect on reshaping cancer management
The Journal of Liquid Biopsy,
Journal Year:
2025,
Volume and Issue:
unknown, P. 100293 - 100293
Published: March 1, 2025
Liquid
biopsy
(LB)
has
emerged
as
a
transformative
tool
in
oncology,
providing
minimally
invasive
approach
for
tumor
detection,
molecular
characterization,
and
real-time
treatment
monitoring.
By
analyzing
circulating
DNA
(ctDNA),
cells
(CTCs),
extracellular
vesicles
(EVs),
microRNA
(miRNA),
LB
enables
comprehensive
profiling
without
the
need
traditional
tissue
biopsies.
Over
past
decade,
research
this
field
expanded
exponentially,
leading
to
integration
of
into
clinical
practice
specific
cancer
types,
including
lung
breast
cancer.
In
2024,
Journal
Biopsy
(JLB)
published
innovative
studies
exploring
latest
advancements
technologies,
biomarkers,
their
applications
minimal
residual
disease
(MRD)
monitoring,
therapy
response
assessment.
This
review
synthesizes
recent
findings
on
role
monitoring
across
different
with
particular
focus
newly
context
within
translational
research.
Additionally,
it
highlights
emerging
techniques
such
fragmentomics,
artificial
intelligence,
multiomics,
paving
way
more
precise,
personalized
decisions.
Despite
these
advancements,
challenges
remain
standardizing
methodologies,
optimizing
validation,
integrating
routine
oncological
workflows.
mini-review
evolving
landscape
its
potential
revolutionize
diagnosis,
therapeutic
decision-making,
ushering
new
era
precision
oncology.
Language: Английский
Latest Research Progress of Liquid Biopsy in Tumor—A Narrative Review
Cancer Management and Research,
Journal Year:
2024,
Volume and Issue:
Volume 16, P. 1031 - 1042
Published: Aug. 1, 2024
Human
life
expectancy
is
significantly
impacted
by
cancer,
with
liquid
biopsy
emerging
as
an
advantageous
method
for
cancer
detection
because
of
its
noninvasive
nature,
high
accuracy,
ease
sampling,
and
cost-effectiveness
compared
conventional
tissue
techniques.
Liquid
shows
promise
in
early
detection,
real-time
monitoring,
personalized
treatment
various
cancers,
including
lung,
cervical,
prostate
offers
innovative
approaches
diagnosis
management.
By
utilizing
circulating
tumor
DNA,
cells,
exosomes
biomarkers,
enables
the
tracking
progression.
Various
techniques
commonly
used
sciences
research,
such
polymerase
chain
reaction
(PCR),
next-generation
sequencing
(NGS),
droplet
digital
PCR,
are
employed
to
assess
progression
on
basis
different
indicators.
This
review
examines
latest
advancements
markers-circulating
DNA
(ctDNA),
cells
(CTCs),
exosomes-for
over
past
three
years,
a
focus
their
methodologies
clinical
applications.
It
encapsulates
pivotal
aims
biopsy,
therapy
response
prediction,
prognostication,
relevance
minimal
residual
disease,
while
also
addressing
challenges
facing
routine
adoption.
combining
research
practical
experiences,
this
work
focuses
discussing
significance
methylation
biomarkers
applications
screening,
auxiliary
diagnosis,
companion
recurrence
monitoring.
These
discussions
may
help
enhance
application
throughout
entire
process
treatment,
thereby
providing
patients
more
precise
effective
plans.
Language: Английский
Genomics and the early diagnosis of lung cancer
Francesco Pepe,
No information about this author
Tancredi Didier Bazan Russo,
No information about this author
Valerio Gristina
No information about this author
et al.
Personalized Medicine,
Journal Year:
2025,
Volume and Issue:
unknown, P. 1 - 10
Published: April 21, 2025
Lung
cancer
(LC)
remains
the
leading
cause
of
cancer-related
mortality
worldwide,
with
most
cases
diagnosed
at
advanced
stages,
resulting
in
poor
survival
rates.
Early
detection
significantly
improves
outcomes,
yet
current
screening
methods,
such
as
low-dose
computed
tomography
(LDCT),
are
limited
by
high
false-positive
rates,
radiation
exposure,
and
restricted
eligibility
criteria.
This
review
highlights
transformative
potential
genomic
molecular
technologies
advancing
early
LC.
Key
innovations
include
liquid
biopsy
tools,
circulating
tumor
DNA
(ctDNA)
cell-free
(cfDNA)
analysis,
which
offer
minimally
invasive
approaches
to
detect
tumor-specific
genetic
epigenetic
alterations.
Emerging
biomarkers,
including
methylation
signatures,
cfDNA
fragmentomics,
multi-omics
profiles,
demonstrate
improved
sensitivity
specificity
identifying
early-stage
tumors.
Advanced
platforms
like
next-generation
sequencing
(NGS)
machine-learning
algorithms
further
enhance
diagnostic
accuracy.
Integrated
that
combine
data
LDCT
imaging
artificial
intelligence
(AI)
show
promise
addressing
limitations
improving
risk
stratification
nodule
characterization.
The
also
explores
multi-cancer
assays
precision
strategies
tailored
for
diverse
at-risk
populations.
By
leveraging
these
advancements,
clinicians
can
achieve
earlier
diagnoses,
reduce
unnecessary
procedures,
ultimately
decrease
LC
mortality.
Language: Английский
Recent advances in the use of liquid biopsy for the diagnosis and treatment of lung cancer
Valerio Gristina,
No information about this author
Gianluca Russo,
No information about this author
Tancredi Didier Bazan Russo
No information about this author
et al.
Expert Review of Respiratory Medicine,
Journal Year:
2024,
Volume and Issue:
unknown, P. 1 - 11
Published: Nov. 3, 2024
Introduction
In
the
era
of
precision
medicine,
liquid
biopsy
rapidly
emerges
as
an
integrative
diagnostic
tool
to
successfully
stratify
solid
tumor
patients
in
accordance
with
molecular
fingerprinting.
As
matter
fact,
a
plethora
analytes
may
be
isolated
from
biosources
supporting
potential
application
several
clinical
scenarios.
Despite
this
promising
role,
is
drastically
affected
by
low
abundance
biological
matrix
requiring
highly
sensitive
technologies,
trained
personnel,
and
optimized
procedures
administrate
revolutionary
practice.
Language: Английский